Background-Premature treatment discontinuation and loss to follow-up (LTFU) with unknown outcomes leave uncertainty about the true efficacy and safety of a treatment and a lack of confidence in the results of any trial. We reviewed the extent of (and trends over time in) reporting LTFU and treatment discontinuation in large studies in chronic heart failure published since 1990. Methods and Results-Online databases were systematically reviewed to identify randomized controlled clinical trials (RCTs) in chronic heart failure with >400 participants and utilizing all-cause mortality as a component of the primary or secondary end point. Assessments were made of documentation of treatment discontinuation, LTFU, inclusion of and completeness of a Consolidated Standards Of Reporting Trials (CONSORT) diagram, and whether LTFU was differentiated from withdrawal of consent. Sixty-eight trials were identified, with >154 000 participants. Reasons for treatment discontinuation in pharmacotherapy trials were infrequently reported (35%), particularly in a CONSORT diagram (20%). Eighty-three percent of trials reported LTFU, although only 34% of these differentiated LTFU for vital status from withdrawal of consent. Use of a CONSORT diagram increased over time, although reporting of LTFU in the CONSORT diagram remained low overall at 35%. Conclusions-Participant flow through RCTs in chronic heart failure has not been uniformly reported, and the use of a complete CONSORT diagram has been low, although it seems to be improving. All study participants should be accounted for within a CONSORT diagram in any RCT to enable the practicing cardiologist to interpret how the results should influence his/her clinical practice. (Circ Heart Fail. 2016;9:e002842.
W ell-conducted prospective, randomized, double-blind, controlled trials are considered the gold standard test of new treatments for disease, are at the core of evidence-based medicine and underpin clinical guidelines. The integrity of clinical trials may be threatened in several ways. One is when patients discontinue randomized therapy prematurely. If substantial numbers of patients stop active therapy, it may not be possible to show a difference from placebo (or between one active substance and another). This problem may be compounded by patients randomly allocated to placebo receiving open label active therapy. However, the greatest contemporary threat is considered to be to patients discontinuing or withdrawing from the trial, that is, withdrawing from the protocol-specified assessments needed to evaluate efficacy and safety. Although related, these 2 problems are distinct in that withdrawal from study treatment should not necessarily lead to withdrawal from the trial, but these 2 types of withdrawal are often confused by investigators and even trial sponsors. Withdrawal from trial follow-up or loss to follow-up (LTFU) has recently been raised as a concern by regulatory agencies. 1 LTFU, with unknown outcomes such as hospitalization and death in a substantial proportion of randomized patients, leaves uncertainty about the true efficacy and safety of a treatment and translates to a lack of confidence in the results of the trial. Consequently, it is crucial that both premature study drug discontinuation and LTFU should be minimized and that the frequency of occurrence of both should be clearly reported on completion of a trial. Efforts have been made to improve reporting of clinical trials with LTFU Reporting in Chronic Heart Failure Trials the publication of the CONsolidated Standards Of Reporting Trials (CONSORT) statement. [2] [3] [4] These statements were first published in 1996 and updated in 2001 and 2010. This guidance for authors includes a checklist and flow diagram detailing participants' status through a trial, including LTFU and treatment discontinuation. Adherence to CONSORT guidance has been shown to improve reporting of clinical trial data. 5 As pharmacological and device treatment is at the core of disease modifying therapy for all patients with chronic heart failure (CHF), we examined how robust the reporting of the randomized controlled clinical trials (RCTs) underpinning the use of drugs and devices is in this condition. Specifically, we reviewed reporting of discontinuation of study drug, LTFU and the use of CONSORT figures in all large device and pharmacotherapy trials in CHF published since 1990.
Methods

Literature Search
Medline and Embase databases were searched with the terms heart or cardiac and failure as title or keywords. Standard filters were used to limit the search to include articles on or after January 1, 1990, including only human participants, published in the English language, and of RCTs. The search was carried out on January 7, 2015. Abstracts and publications were independently reviewed by 2 readers (R.C. and G.W.; Figure 1 ). Discrepancies were resolved through discussion and reviewed by a third reader (J.M.). Inclusion criteria were RCTs of a pharmacological or device (implantable cardioverter defibrillator or cardiac resynchronization therapy) intervention, studies in CHF, and ≥400 participants. Manuscripts were excluded if mortality was not a component of the prespecified primary or secondary end point. We also excluded studies of acute heart failure and subgroup analyses.
Data Extraction and Analysis
Each article was independently reviewed by 2 readers (R.C. and G.W.). Disagreements and discrepancies were resolved by a third reviewer (J.M.). Tables, figures, and text of the primary paper and appendix were reviewed, and the following information gathered: trial characteristics (publication date, journal, total number of participants, number of participants per treatment arm, and mortality), documentation of LTFU and treatment discontinuation including reasons (for pharmacotherapy trials), and inclusion of and content of a CONSORT diagram. We documented whether LTFU was reported as loss of vital status only, loss of data pertaining to the primary end point, and whether "withdrawal of consent" was described. If the above data were not described in the primary results paper or appendix, then a search of subsequent subanalyses and other sources of information were carried out (eg, Food and Drug Administration [FDA] reports). Reporting of the use of open-label therapy in the placebo arm of pharmacotherapy trials was recorded. Potential availability of open-label pharmacotherapy was estimated by comparing FDA drug authorization dates to trial recruitment and follow-up dates. Weighted means (by number of participants) and standard deviation were calculated using the Bland and Kerry method. 6 Table 1 summarizes the 68 qualifying RCTs in CHF which enrolled >400 patients and were published since 1990. The details of the trials are shown in Table I in the Data Supplement. A description of CHF trial acronyms is provided in Table II in the Data Supplement. The majority of studies were published in the New England Journal of Medicine (n=32, 47%) or The Lancet (n=14, 21%). The most common primary end points were all-cause mortality or a composite mortality-morbidity end point. A composite end point was commonly used in more recent studies and often included cardiovascular, rather than all-cause mortality. Most pharmacotherapy studies were placebo controlled (n=42, 72%).
Results
Discontinuation of Study Treatment
Nine of the 58 pharmacotherapy trials did not report rates of discontinuation of study drug for any reason other than death or because of an adverse event in the primary results paper, although these data were subsequently published in FDA reports for 2 trials (African-American Heart Failure Trial [A-HeFT] and Valsartan Heart Failure Trial [Val-HeFT]). 75 Of these 9, 3 reported rates of discontinuation for adverse events only. A description of the reasons for study drug discontinuation was provided in only 20 trials. 
Open Label Use of Study Treatment
Loss to Follow-Up
LTFU for at least vital status (ie, whether the patient was alive or dead at the end of the study) was reported in the primary results paper of all but 7, 9, 18, 21, 26, 30, 59, 62, 63, 70 LTFU for vital status was not described in the primary results paper of Val-HeFT, 33 but was published in a subsequent FDA report. 75 The weighted mean LTFU reported was 1.4%, with a range from 0% to 14.8%. The weighted mean LTFU was higher in device trials compared with pharmacotherapy trials, 2.9% versus 1.3%, respectively. Six trials of pharmacotherapy reported total LTFU of >5%, and the rate of LTFU did not seem to be related to trial duration: Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure (STAT-CHF) (duration 45 months, LTFU 11.6%), 14 Cardiac Insufficiency Bisoprolol Study (CIBIS) III (14.6, 11.8%), 40 Atrial Fibrillation and Congestive Heart Failure (AF-CHF) (37, 5.7%), 45 Cardiac Insufficiency Bisoprolol Study in Elderly (CIBIS-ELD) (3, 9.4%), 55 Sertraline Against Depression and Heart Disease in Chronic Heart Failure (SADHART-CHF; 26.2, 6.2%), 54 and Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH; 21, 5.6%) 72 ; in the last 3 trials "withdrawal of consent" was assumed to equate to LTFU. Of the 10 device trials, 3 reported LTFU of >5%: Multicenter Au-tomatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT) (duration 29 months, LTFU 5.4%), Biventricular versus Right Ventricular Pacing in Heart Failure Patients with Atrioventricular Block (BLOCK-HF) (37, 14.8%), and Echocardiography Guided Cardiac Resynchronization Therapy (ECHO-CRT) (19, 6.4%). LTFU reporting improved during the period reviewed, with all but 3 studies from 2002 onwards reporting LTFU. In most trials, it was not clear whether follow-up for outcomes other than death was complete. One notable exception was Heart failure Endpoint evaluation of Angiotensin II Antagonist Losartan study (HEAAL). 51 In HEAAL, the authors reported that the status for the primary end point (death from any cause or heart failure hospitalization) was unknown for 41 (2%) patients in the 150 mg (losartan) group and 54 (3%) patients in the 50 mg group, and vital status was unknown for 48 (2%) and 62 (3%) patients, respectively. The Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) investigators also provided a CONSORT diagram in an online appendix which potentially included complete patient dispositions. 57 However, this was difficult to interpret, showing the number of patients with a complete follow-up or end point (745/1142 patients assigned to warfarin and 761/1163 assigned to aspirin), those experiencing a primary end point (302 and 320), the number in which only vital status was known (46 and 44) and those lost to follow-up (17 and 18), and we could not reconcile the numbers.
Withdrawal of Consent
A further problem was the reporting of and interpretation of "withdrawal of consent." This has only been reported in more recent trials. When reported, it was usually unclear whether withdrawal of consent necessarily equated to LTFU; examination of patient disposition in various trials suggested that in most it did (or was implied eg, Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure [STAT-CHF], Journal, n (%)
The Lancet 14 (21) 14 (24) 14, 31, 35, 37, 40, 44, 53, 57, [66] [67] [68] [69] whereas in others it did not (ECHOS, SADHART-CHF, and CIBIS-ELD). 49, 54, 55 One example of a trial that did report patient status clearly in this respect was Omipatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events [OVERTURE], where the authors reported 1.0% and 0.8%, respectively, were lost to follow-up for assessment of vital status and 0.9% and 0.4%, respectively, withdrew consent to be monitored for end points. 34
Provision of a CONSORT Diagram
Of the 68 trials reviewed, 58 were published after the first CON-SORT statement. Of these, 29 were published with a CONSORT type figure in the main paper or as an appendix ( (Table 3 ). Of the studies with a CONSORT diagram, most described LTFU within the flow diagram (24 studies). However, only 10 of the pharmacotherapy studies reported treatment discontinuation within the CONSORT diagram. Furthermore, only 3 studies provided reasons for treatment discontinuation within the CONSORT diagram (Follow-Up Serial Infusions of Nesiritde trial [FUSION II], WATCH, and SADHART-CHF). 43, 54, 64 Before the first CONSORT statement in 1996, only 1 study of CHF reported patient flow through the study with a flow diagram (Xamoterol-HF). 7 Overall, CONSORT diagram use increased during the time period reviewed after each successive CONSORT guidance publication ( Table 2 ). Of the 10 device trials, only the most recent trials (RAFT, BLOCK-HF, and ECHO-CRT) used a CONSORT diagram. Studies with a CONSORT diagram documented LTFU (either within the text, tables, or diagrams) more frequently (93%) than those without (76%). Similarly, treatment discontinuation was more frequently documented (either within the text, tables, or diagrams) in trials of pharmacotherapy with a CONSORT diagram (96%) than without (74%).
Discussion
Loss of participants during the course of a randomized controlled trial (sometimes referred to as dropouts or attrition) 76 can introduce bias that may make interpretation of the results of the trial difficult or even question their validity. [77] [78] [79] [80] [81] [82] LTFU introduces bias if the characteristics of participants LTFU differ between the randomized groups and the characteristics that differ are related to the trial's outcomes, especially if the proportion of participants LTFU differs between treatment groups. [77] [78] [79] [80] [81] [82] For example, patients who are sicker at baseline are more likely to experience worsening of their condition; worsening may lead to withdrawal from the trial and the patient may die. Both worsening and death may be important outcomes in the trial and, if missing, will result in the trial giving an incomplete report of the true picture of what happens to patients with the condition. Should withdrawal from the trial occur more commonly in one treatment group than the other (eg, because of benefit or harm from the investigational therapy), this non-random loss of data will result in a biased assessment of the effect of treatment. The same considerations apply to adverse effects related to study treatment and reliable estimation of the overall risk:benefit ratio. Although it is often reported that serious bias does not occur until the proportion of LTFU is >20% and that little bias is likely if the proportion is <5%, 77 this rule-ofthumb has been questioned and even a LTFU proportion of 5% is potentially important in trials with low event rates. 83 A concrete example of this is reflected in the FDA concern about the Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome ACS 2-Thrombolysis In Myocardial Infarction 51 trial (ATLAS ACS 2-TIMI 51). Of the 15 526 patients randomized, 1294 patients (8.3%) withdrew consent and vital status was not ascertained in 1117 patients (7.2%); this number exceeded the total number of patients with a primary end point (n=1002). 84 Indeed, the primary composite end point could not be evaluated in 2402 patients (15.5%). Consequently, transparency in relation to completeness of follow-up is a crucially important aspect of the reporting of clinical trials; LTFU should be described in the primary trial publication, is an important consideration in the approval process for new treatments (as indicated above) and is part of the grading of levels of evidence used in some guidelines. 85 Use of a CONSORT figure is recommended as the means of providing this information.
We found that 11 of the 68 CHF trials (16.1%) did not report LTFU. This is a similar proportion to that reported in a previous survey of 235 trials published in the 5 leading general medical journals, 82 although another similar analysis reported that assessment of LTFU was difficult from the descriptions given in the trial results papers. 80 Description of study drug discontinuation rates in pharmacotherapy trials was also incomplete, both overall (16% did not report discontinuation because of reasons other than death) and for specific reasons (only 35% reported reasons for specific discontinuation).
Reporting of LTFU and treatment discontinuation in CHF trials improved over the 2 decades analyzed. Inclusion of a CONSORT type diagram increased after the initial guidance in 1996, and with each subsequent CONSORT statement. Authors utilizing a CONSORT diagram were more likely to document LTFU and treatment discontinuation. Although most journals endorse the CONSORT approach (with the exception of the American Heart Journal), inclusion of a CONSORT diagram varied between journals, with the Lancet, the Journal of the American Medical Association, and Circulation Heart Failure having the highest proportional use of such diagrams. However, only 3 studies reported patient disposition completely within the CONSORT diagram (FUSION II, WATCH, and SADHART-CHF), 43, 54, 72 that is, detailed LTFU and treatment discontinuations, including the reasons for each. Of the 68 CHF trials included in this analysis, 32 were published in the New England Journal of Medicine but only 8 of these featured a CONSORT diagram in the primary paper or appendix. This perhaps reflects the New England Journal of Medicine endorsing the CONSORT methodology in 2004, and instructions for authors state that authors may provide a CONSORT diagram. Since 2004, over half of CHF studies meeting the inclusion criteria for this review and published in the New England Journal of Medicine featured a CONSORT diagram. Other journals, LTFU Reporting in Chronic Heart Failure Trials such as the Lancet and the Journal of the American Medical Association are more explicit in their requirements for authors to comply with the CONSORT 2010 statement.
The robustness of reporting of trials of device therapy in CHF has previously been questioned. 86 The proportion of studies reporting LTFU was similar between device and pharmacotherapy trials, at 80 and 84%, respectively. However, the weighted mean LTFU was higher in device versus pharmacotherapy trials at 2.9% and 1.3%, respectively. Use of a CONSORT figure to describe patient flow differed between the 2 types of CHF trial studied, with 46% of pharmacotherapy and 30% of device trials using a CONSORT figure. However, the use of a CONSORT figure did improve latterly, with the 3 most recent device studies reporting patient flow with a CONSORT figure, although there was ambiguity about withdrawal of consent and whether this represented withdrawal from follow-up. Not only did reporting of LTFU and CONSORT diagram use improve during the study period, but the weighted average proportion of participants LTFU in the trials analyzed was lower than in previous studies: 1.4% (range, 0%-14.8%) compared with 6% (2%-14%) reported by Akl et al 82 and 7% (0.1%-48%) by Dumville et al. 78 The reason for the difference between the current and previous studies is not clear but cannot be attributed entirely to year of publication. However, our findings reassure the practicing cardiologists about the robustness of reporting of RCTs of pharmacotherapy and device therapy in CHF.
Despite these encouraging trends, there is room for further improvement. Confusing terminology is still often used, making interpretation of participant flow through a trial difficult. The term LTFU was often used in an ambiguous fashion, especially in trials where the primary end point was not all-cause mortality. A minority of trials differentiated LTFU for vital status from LTFU with respect to the primary end point, for example, a mortality-morbidity composite. This issue has also been highlighted by Toerien et al 80 Does this mean withdrawal from the study treatment, from some planned follow-up/study procedures (eg, in-person visits), or from all active follow-up? What about passive follow-up, for example, through medical records or death registers? A particular problem in more recent trials is the term "withdrawal of consent." It is often not clear whether this precludes any further follow-up of participants, even for vital status. Indeed, "withdrawal of consent" may have a different implication for followup, depending on the country of recruitment. Some countries require a patient be removed from passive follow-up if they withdraw consent to participate in the study (eg, Germany), where others (United Kingdom) can passively follow-up patients for end point analyses through the use of national databases unless the patient explicitly requests that this does not happen. We recommend that the phrase "withdrawal of consent" not to be used in a nonspecific way and that, instead, patients are asked to list, from a menu of options, what sort of follow-up they are willing to accept even if they do not wish to continue to return for study visits. These might include telephone follow-up, in person, contact with a primary care physician, follow-up through medical records, and tracking through national registers or public records. Of course, the patient may choose to refuse any form of follow-up at all. These details should be made explicitly clear to the reader, and we have provided examples of less ambiguous phrases (Table 4 ). Other useful metrics which help in the interpretation of LTFU but infrequently reported are the number/proportion of patients discontinuing study follow-up after experiencing a primary nonfatal end point (as opposed to the number/proportion discontinuing before any recognized event) and the proportion of overall potential follow-up time for which end point ascertainment took place. The latter was reported in SADHART-CHF. 54 With the growing internationalization of trials, it may also be appropriate to report study-treatment discontinuation rates and LTFU by region or country. 87, 88 Reporting of the other aspects of the conduct of trials that might affect their integrity, that is, premature discontinuation of randomized therapy and crossover to open-label active therapy was also limited. The latter consideration only applies to a limited number of studies, that is, where the treatment under investigation (or something similar) is available for prescription and is difficult to fully evaluate, for example, because such treatment may not be available in all countries included in the trial. The former consideration is, however, applicable to all trials of pharmacological therapy. As described above, we found description of discontinuation rates to be incomplete, both overall and for specific reasons. Overall rates of discontinuation of study drug can be reported in the CONSORT diagram. We think that all prescribers of therapies and patients who take therapies also have the right to see a detailed breakdown of causes of discontinuation of study drug. We suspect that word restrictions by journals may limit the reporting of such information although the increasing availability of online supplementary appendices alongside papers should remove this obstacle. A useful related metric infrequently described is the time spent on each randomized therapy. This was only reported in SADHART-CHF. 54
Recommendations for RCT Reporting
We think that documentation of patients flow through a study should be standardized. LTFU, treatment discontinuation, and withdrawal of consent should be defined, subcategorized, and systematically recorded. The time points during follow-up of these occurrences should be documented. This will allow readers to make an informed decision about the results, and therefore how a trial should influence the reader's practice. Authors should make clear the numbers of participants for whom the primary end point status was unknown and differentiate this from loss of vital status, rather than use vague terms, such as "withdrawal" (Table  4 ). Authors should detail the number of participants who stop blinded therapy and take open-label therapy (where appropriate). Authors should also detail time spent on the study for all participants, especially those not completing the study protocol and full follow-up. This will allow readers to interpret the potential effect that participants dropout may have on the trial results. It is our opinion that the CONSORT diagram should be adapted to include these data ( Figure 2 ). Specifically, we think the follow-up section of the CONSORT diagram should include the number of participants with unknown primary end point status, unknown vital status, number of participants who discontinue study intervention (including reasons and those who take open label therapy), and the duration of follow-up. At the least, utilizing a CONSORT diagram should be mandatory when reporting a clinical trial.
The main limitation of this study is that we limited our analysis to trials of device and pharmacotherapy, and we did not include the other treatment options available in CHF (such as remote monitoring, exercise prescription, or ventricular assist devices), or acute heart failure trials. This was because we wished to examine reporting of LTFU, and robustness of trial reporting in general, in classes of therapy that have been shown to reduce mortality in patients with CHF.
Conclusions
The findings of this systematic review are not only important to those involved in the design and reporting of RCTs but also to the practicing cardiologist. Although reporting of LTFU in RCTs of device and pharmacotherapy in CHF has improved, this could and should be more complete. However, the proportion of participants LTFU in CHF trials was less than reported in other conditions, reassuring the practising Cardiologist that the evidence base for device and pharmacotherapy in CHF is particularly robust. Nevertheless, Cardiologists should pay close attention to the reporting of LTFU when interpreting the results of RCTs, and, ultimately, in deciding how RCTs should influence their clinical practice. LTFU during RCTs should be fully reported in a CONSORT diagram to allow readers to better interpret the results.
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